Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs – technology appraisal guidance (TA445)

NICE has approved the use of certolizumab pegol alone (or in combination with methotrexate (MTX)) or secukinumab alone (or with MTX) as options for treating active psoriatic arthritis in adults provided certain conditions are met.

Certolizumab pegol is recommended if it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199) or the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks.

 

Secukinumab is similarly recommended if it is used as described in the NICE technology appraisal guidance TA199 or the person has had a TNF‑alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks, or TNF‑alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance TA199).

 

Both drugs are only recommended if the respective companies provide them as agreed in the patient access schemes.